Conditions: Generalized Anxiety Disorder Comorbid Opiate Dependence in Remission Status Post Methadone-Maintenance Treatment
Keywords: Generalized Anxiety Disorder Opiate Dependence Methadone-Maintenance Drug Addiction Treatment
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 14
Healthy volunteers: no

Brief summary:
This is a 16 week study of the efficacy of quetiapine in treating symptoms of generalized anxiety disorder (GAD) in subjects with comorbid opiate dependence. The study will be conducted in a prospective, randomized, double-blind, and placebo-controlled fashion. Study subjects will be inpatients at a residential drug-treatment facility, enrolled in a 1 year methadone-to-abstinence treatment plan. Subjects will be randomized to receive either quetiapine or placebo in addition to ongoing drug addiction treatment. Subjects will be followed for 16 weeks and a variety of psychometric assessments will be made.

Hypothesis One: Compared to placebo, Quetiapine will demonstrate a greater reduction in symptoms of anxiety in subjects with GAD and remitted comorbid opiate abuse.

Exploratory Hypotheses: Compared to placebo, Quetiapine will demonstrate a greater improvement in psychosocial functioning and compliance with community norms in subjects enrolled in a residential drug addiction treatment facility.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Quetiapine
Intervention descriptions: intervention 1: Dosage is 50 - 300 mg, once daily, at bedtime.

Protocol document: